These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 12835615)

  • 1. NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women.
    van der Hel OL; Peeters PH; Hein DW; Doll MA; Grobbee DE; Kromhout D; Bueno de Mesquita HB
    Pharmacogenetics; 2003 Jul; 13(7):399-407. PubMed ID: 12835615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer.
    Lee KM; Park SK; Kim SU; Doll MA; Yoo KY; Ahn SH; Noh DY; Hirvonen A; Hein DW; Kang D
    Cancer Lett; 2003 Jul; 196(2):179-86. PubMed ID: 12860276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GSTM1 null genotype, red meat consumption and breast cancer risk (The Netherlands).
    van der Hel OL; Peeters PH; Hein DW; Doll MA; Grobbee DE; Ocké M; Bueno de Mesquita HB
    Cancer Causes Control; 2004 Apr; 15(3):295-303. PubMed ID: 15090724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
    García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
    Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
    Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP
    Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.
    Hirvonen A; Saarikoski ST; Linnainmaa K; Koskinen K; Husgafvel-Pursiainen K; Mattson K; Vainio H
    J Natl Cancer Inst; 1996 Dec; 88(24):1853-6. PubMed ID: 8961976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk (The Netherlands).
    van der Hel OL; Bueno-de-Mesquita HB; van Gils CH; Roest M; Slothouber B; Grobbee DE; Peeters PH
    Cancer Causes Control; 2005 Aug; 16(6):675-81. PubMed ID: 16049806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutathione S-transferase mu1 and N-acetyltransferase 2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls.
    Nyberg F; Hou SM; Hemminki K; Lambert B; Pershagen G
    Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):875-83. PubMed ID: 9796632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutathione S-transferase (GST) M1, T1 and N-acetyltransferase 2 (NAT2) polymorphisms and urothelial cancer risk with tobacco smoking.
    Tsukino H; Nakao H; Kuroda Y; Imai H; Inatomi H; Osada Y; Katoh T
    Eur J Cancer Prev; 2004 Dec; 13(6):509-14. PubMed ID: 15548945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSTM1 and GSTT1 polymorphisms and postmenopausal breast cancer risk.
    Zheng W; Wen WQ; Gustafson DR; Gross M; Cerhan JR; Folsom AR
    Breast Cancer Res Treat; 2002 Jul; 74(1):9-16. PubMed ID: 12150456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women.
    McGrath M; Michaud D; De Vivo I
    BMC Cancer; 2006 Oct; 6():239. PubMed ID: 17026750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential interactions between GSTM1 and NAT2 genotypes on aromatic DNA adduct level and HPRT mutant frequency in lung cancer patients and population controls.
    Hou SM; Fält S; Yang K; Nyberg F; Pershagen G; Hemminki K; Lambert B
    Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):133-40. PubMed ID: 11219770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population.
    Rouissi K; Ouerhani S; Marrakchi R; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; El Gaaied AB
    Cancer Genet Cytogenet; 2009 Apr; 190(2):101-7. PubMed ID: 19380028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
    Okkels H; Sigsgaard T; Wolf H; Autrup H
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk.
    Millikan RC; Pittman GS; Newman B; Tse CK; Selmin O; Rockhill B; Savitz D; Moorman PG; Bell DA
    Cancer Epidemiol Biomarkers Prev; 1998 May; 7(5):371-8. PubMed ID: 9610785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of DNA and protein adducts in smokers by genetic polymorphisms in GSTM1,GSTT1, NAT1 and NAT2.
    Godschalk RW; Dallinga JW; Wikman H; Risch A; Kleinjans JC; Bartsch H; Van Schooten FJ
    Pharmacogenetics; 2001 Jul; 11(5):389-98. PubMed ID: 11470992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetyltransferase 2 (NAT2) genotypes, cigarette smoking, and the risk of breast cancer.
    Alberg AJ; Daudt A; Huang HY; Hoffman SC; Comstock GW; Helzlsouer KJ; Strickland PT; Bell DA
    Cancer Detect Prev; 2004; 28(3):187-93. PubMed ID: 15225898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women.
    Deitz AC; Zheng W; Leff MA; Gross M; Wen WQ; Doll MA; Xiao GH; Folsom AR; Hein DW
    Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):905-10. PubMed ID: 11008907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAT2 slow acetylator genotype as an important modifier of breast cancer risk.
    Sillanpää P; Hirvonen A; Kataja V; Eskelinen M; Kosma VM; Uusitupa M; Vainio H; Mitrunen K
    Int J Cancer; 2005 Apr; 114(4):579-84. PubMed ID: 15609332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer.
    Firozi PF; Bondy ML; Sahin AA; Chang P; Lukmanji F; Singletary ES; Hassan MM; Li D
    Carcinogenesis; 2002 Feb; 23(2):301-6. PubMed ID: 11872636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.